|
|
Vol. 10.34 – 30 August, 2022
|
|
|
|
|
|
|
|
Ablation of RASA2 in multiple preclinical models of T cell receptor and CAR T cell therapies prolonged survival in mice xenografted with either liquid or solid tumours.
[Nature]
|
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
|
Researchers assessed whether tumor immune contexture influenced clinical outcomes after axicabtagene ciloleucel. They evaluated the tumor microenvironment of 135 pre-treatment and post-treatment tumor biopsies taken from 51 patients in the ZUMA-1 Phase II trial.
[Nature Medicine]
|
|
|
|
|
|
To complement GWASs and better define actionable biological targets, scientists analyzed sequence data from more than 30,000 patients with Crohn’s disease and 80,000 population controls.
[Nature Genetics]
|
|
|
|
|
|
The authors analyzed the effects of decitabine on myeloid-derived suppressor cells (MDSCs) from patients with immune thrombocytopenia, both in vitro and in vivo, and found that low-dose decitabine promoted the generation of MDSCs, and enhanced their aerobic metabolism and immunosuppressive functions.
[Blood]
|
|
|
|
|
|
Investigators examined the heterogeneity of CD8+ T cells in tumors, metastatic lymph nodes, and peripheral blood from patients with early breast cancer.
[Science Immunology]
|
|
|
|
|
|
Scientists identified Ly6C+/CD11b+ inflammatory monocytes as the primary source of IFNβ and found that active type-I-IFN signaling in tumor-infiltrating inflammatory monocytes was associated with T cell expansion in patients treated with immune checkpoint blockade.
[Nature Communications]
|
|
|
|
|
|
The authors generated an atlas of 166,533 cells from ten gastric cancer patients with matched paratumor tissues and blood. Their results showed tumor-associated stromal cells had upregulated activity of Wnt signaling and angiogenesis, and were negatively correlated with survival.
[Nature Communications]
|
|
|
|
|
|
Researchers demonstrated that PD-1+CD8+ T cells functioned as an independent adverse prognosticator in gastric cancer (GC). In addition, an abundance of intratumoral PD-1+CD8+ T cells indicated worse chemotherapeutic responsiveness to fluorouracil in Stage III GC patients.
[British Journal of Cancer]
|
|
|
|
|
|
Scientists evaluated long-term survival and late effects in 137 patients affected by thalassemia major who received an allogeneic hematopoietic cell transplantation.
[Bone Marrow Transplantation]
|
|
|
|
|
|
Investigators showed that the sequential use of different T cell redirection therapies was possible and could lead to deep and durable responses following relapse after bispecific antibody therapy in relapsed/refractory multiple myeloma.
[Blood Advances]
|
|
|
|
|
|
Researchers constructed and screened binders in an single chain Fv format library to generate a new anti-B7-H3 CAR-T with favorable properties. This allowed access to numerous specificities ready formated for CAR evaluation.
[Molecular Therapy-Oncolytics]
|
|
|
|
|
|
The authors investigated the mechanistic role of cytokine-induced SH2 protein (CISH) in regulating human T cell effector function in solid tumors and demonstrated that CRISPR/Cas9 disruption of CISH enhanced tumor-infiltrating lymphocyte neoantigen recognition and response to checkpoint blockade.
[Med]
|
|
|
|
|
|
All patients enrolled in the VITAL trial of maintenance gemogenovatucel-T vs. placebo as front-line therapy with homologous recombination proficient stage IIIB-IV newly diagnosed ovarian cancer underwent NanoString gene expression analysis.
[Communications Medicine]
|
|
|
|
|
|
|
|
In light of the immune checkpoint inhibition revolution in cancer therapy, scientists review eosinophil–lymphocyte interactions in the tumor microenvironment.
[Nature Immunology]
|
|
|
|
|
|
Investigators summarize the progress of immunotherapy for the treatment of hepatocellular carcinoma including immune checkpoint inhibitors, liver cancer vaccines, and cellular therapies.
[Clinical and Experimental Medicine]
|
|
|
|
|
|
|
|
Regen BioPharma, Inc. announced the development of a novel immunotherapy for treatment of solid tumors. The current approach developed by the company involves initial treatment of the tumor microenvironment with cells of the innate immune system called CAR-M and CAR-NK cells.
[Regen BioPharma, Inc. (Cision US, Inc.)]
|
|
|
|
|
|
Century Therapeutics, Inc. announced that the company has been notified by the US FDA that the company’s ELiPSE-1 clinical study may proceed to assess CNTY-101 in patients with relapsed or refractory CD19 positive B cell malignancies.
[Century Therapeutics, Inc.]
|
|
|
|
|
|
|
|
November 10 – 12, 2022
Bordeaux, France
|
|
|
|
|
|
|
|
|
|
|
STEMCELL Technologies, Inc. – Vancouver, British Columbia, Canada
|
|
|
|
|
|
|
Genentech, Inc. – South San Francisco, California, United States
|
|
|
|
|
|
|
Olivia Newton-John Cancer Research Institute – Victoria, Australia
|
|
|
|
|
|
|
Melanoma Institute Australia – Sydney, Australia
|
|
|
|
|
|
|
Dalhousie University – Halifax, Nova Scotia, Canada
|
|
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News